EVEREST trial

Introduction

Study characteristics:

• 4133 adults, with LVEF < 40% hospitalized with worsening congestive heart failure (CHF)

Treatment:

• tolvaptan 30 mg/day vs placebo for at least 60 days
• both groups received standard therapy for CHF

Results: (relative to placebo)

• weight loss greater in tolvaptan group (< 1 kg)
• dyspnea, rales & edema modestly improved in tolvaptan group
• serum Na+ improved (3 meq/L) in tolvaptan group
• mean serum creatinine increased 0.06 mg/dL in tolvaptan group
• thirst & dry mouth more common in tolvaptan group
• no diffences in long term outcome, mortality, hospitalization for CHF exacerbation, or overall health status

More general terms

• clinical trial